U.S., Dec. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07288333) titled 'Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia' on Dec. 15.
Brief Summary: The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: NBI-1117570
Oral administration
DRUG: Placebo
Oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Neurocrine Biosciences
Published by HT Digital Content Services with permission from Health Daily Dig...